Autologous hematopoietic stem cell transplantation in systemic lupus erythematosus patients with cardiac dysfunction: feasibility and reversibility of ventricular and valvular dysfunction with transplant-induced remission
- 7 May 2007
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 40 (1) , 47-53
Abstract
Patients with cardiac dysfunction may be at increased risk of cardiac toxicity when undergoing hematopoietic stem cell transplantation (HSCT), which may preclude them from receiving this therapy. Cardiac dysfunction is, however, common in systemic lupus erythematosus (SLE) patients. While autologous HSCT (auto-HSCT) has been performed increasingly for SLE, its impact on cardiac function has not previously been evaluated. We, therefore, performed a retrospective analysis of SLE patients who had undergone auto-HSCT in our center to determine the prevalence of significant cardiac involvement, and the impact of transplantation on this. The records of 55 patients were reviewed, of which 13 were found to have abnormal cardiac findings on pre-transplant two-dimensional echocardiography or multi-gated acquisition scan: impaired left ventricular ejection fraction (LVEF) (n=6), pulmonary hypertension (n=5), mitral valve dysfunction (n=3) and large pericardial effusion (n=1). At a median follow-up of 24 months (8–105 months), there were no transplant-related or cardiac deaths. With transplant-induced disease remission, all patients with impaired LVEF remained stable or improved; while three with symptomatic mitral valve disease similarly improved. Elevated pulmonary pressures paralleled activity of underlying lupus. These data suggest that auto-HSCT is feasible in selected patients with lupus-related cardiac dysfunction, and with control of disease activity, may improve.Keywords
This publication has 31 references indexed in Scilit:
- Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantationBlood, 2005
- Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: A prospective, long-term, followup studyArthritis & Rheumatism, 2005
- Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosisBone Marrow Transplantation, 2004
- Predictors for severe cardiac complications after hematopoietic stem cell transplantationBone Marrow Transplantation, 2004
- Hematopoietic stem cell transplantation for severe and refractory lupusArthritis & Rheumatism, 2002
- Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fractionBone Marrow Transplantation, 2001
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992
- Prevalence, Morphologic Types, and Evolution of Cardiac Valvular Disease in Systemic Lupus ErythematosusNew England Journal of Medicine, 1988
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982
- ACUTE LETHAL CARDITIS CAUSED BY HIGH-DOSE COMBINATION CHEMOTHERAPYThe Lancet, 1976